Equity Analysis /
United States of America

US : Xilio Therapeutics, Inc. - XLO | Analysis of IL-2 Preclinical Dose Relationships and Lessons from Bempeg Melanoma Miss

    Dane Leone
    Bowen Wu
    Bowen Wu

    Res. Assoc.

    CGS-CIMB
    25 March 2022
    Published by